Last reviewed · How we verify
NCT05043571
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
Phase 1 trial testing CAR T-cell therapy in Lymphoblastic Leukemia, Acute, Childhood in 20 participants. Currently enrolling.
1 November 2026
Quick facts
| Lead sponsor | National University Hospital, Singapore |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 8 September 2021 |
| Primary completion | 1 November 2026 |
| Estimated completion | 1 November 2026 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- CAR T-cell therapy — full drug profile →
Conditions studied
- Lymphoblastic Leukemia, Acute, Childhood — all drugs for Lymphoblastic Leukemia, Acute, Childhood →
- Lymphoblastic Leukemia — all drugs for Lymphoblastic Leukemia →
- Lymphoblastic Leukemia, Acute Adult — all drugs for Lymphoblastic Leukemia, Acute Adult →
- Lymphoblastic Leukemia in Children — all drugs for Lymphoblastic Leukemia in Children →
Sponsor
National University Hospital, Singapore
Who can join
Adults 6 Months to 65, any sex, with Lymphoblastic Leukemia, Acute, Childhood or Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Chimeric antigen receptor T-cell therapy for T-ALL and AML.
Wei W, Yang D, Chen X, Liang D, et al · · 2022 · cited 20× · PMID 36523990 · DOI 10.3389/fonc.2022.967754 -
Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia.
Oh BLZ, Vinanica N, Wong DMH, Campana D. · · 2024 · cited 19× · PMID 38832423 · DOI 10.3324/haematol.2023.283848 -
Current state of CAR-T therapy for T-cell malignancies.
Luo L, Zhou X, Zhou L, Liang Z, et al · · 2022 · cited 19× · PMID 36601636 · DOI 10.1177/20406207221143025 -
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives.
Caracciolo D, Mancuso A, Polerà N, Froio C, et al · · 2023 · cited 18× · PMID 36624522 · DOI 10.1186/s40164-022-00368-w -
Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report.
Gossai NP, Devidas M, Chen Z, Wood BL, et al · · 2023 · cited 18× · PMID 36603187 · DOI 10.1182/blood.2022018653 -
An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.
Patel J, Gao X, Wang H. · · 2023 · cited 13× · PMID 37108359 · DOI 10.3390/ijms24087201 -
CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure?
Maciocia N, Wade B, Maciocia P. · · 2025 · cited 11× · PMID 39715467 · DOI 10.1182/bloodadvances.2023012263 -
Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application.
Huang Z, Fu Y, Yang H, Zhou Y, et al · · 2024 · cited 10× · PMID 38365716 · DOI 10.1186/s12943-024-01947-7
Verify or expand the search:
- PubMed search for NCT05043571
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CAR T-cell therapy
Trials testing the same drug.
- NCT07052305 — NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Sub · Phase 1 · recruiting
- NCT05038696 — ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. · Phase 1 · recruiting
- NCT03919240 — CAR-T Cell Therapy Targeting to CD19 for R/R ALL · Phase 1, PHASE2 · active not recruiting
Other recruiting trials for Lymphoblastic Leukemia, Acute, Childhood
Currently open trials in the same condition.
- NCT05038696 — ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. · Phase 1 · recruiting
- NCT03817320 — PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymph · Phase 1, PHASE2 · active not recruiting
Other National University Hospital, Singapore trials
Trials by the same sponsor.
- NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
- NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
- NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05043571 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
- Last refreshed: 14 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05043571.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing